Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2020-11-12 Capital/Financing Update
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
FORM S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Aprea Therapeutics, Inc. It registers additional shares of common stock under the company's 2019 Equity Incentive Plan. The document includes details about the securities being registered, incorporation by reference of prior filings (such as 10-K and 10-Q reports), and exhibits including legal opinions and consents. Form S-8 is a registration statement used for securities issued under employee benefit plans and is a type of capital raising or equity issuance filing. It is not an annual report, earnings release, or other financial report. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the filing itself, not just an announcement or certification.
2020-11-12 English
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Aprea Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, warrants, debt securities, rights, and units. The document is a detailed prospectus and registration statement for capital raising purposes, describing the terms and conditions of the securities to be offered. This type of filing is related to capital/financing activities and fundraising, not an annual report, earnings release, or other types of filings. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to the clear identification of the form and content.
2020-11-12 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2020, by Aprea Therapeutics, Inc. It announces the issuance of a press release with financial results for the third quarter ended September 30, 2020. The document itself is a current report and includes a press release as an exhibit. The length is 4040 characters, which is relatively short and the document states that the press release is attached as an exhibit. This fits the pattern of a Regulatory Filing (RNS) rather than a full Earnings Release (ER) or Interim Report (IR), as the actual financial results are in the press release exhibit, not fully contained in the document. Therefore, the best classification is Regulatory Filings (RNS).
2020-11-05 English
4
Director's Dealing
2020-10-08 English
SC 13D/A
Major Shareholding Notification
2020-10-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.